Pediatric heart transplantation: Improving results in high-risk patients  by Dellgren, Göran et al.
Objectives: Our institutional experience with 73 pediatric patients undergo-
ing cardiac transplantation between January 1, 1990, and December 31,
1999, was reviewed to determine the impact of unconventional donor and
recipient management protocols implemented to extend the availability of
this therapy.
Methods and results: The introduction of donor blood cardioplegic solution
with added insulin was associated with a significant improvement in patient
and graft survival (hazard ratio [Cox] = 0.25, P = .08), despite significantly
longer ischemic times with this protocol compared with the use of crystalloid-
based donor procurement techniques (P < .01). Eleven patients underwent
intentional transplantation of ABO-incompatible donor hearts with the aid of a
protocol of plasma exchange on bypass. In this subgroup, there were 2 early
deaths caused by nonspecific graft failure (n = 1) and respiratory complica-
tions with mild vascular rejection (n = 1), and there was 1 late death caused by
lymphoma. ABO-incompatible transplantation was not a risk factor for death
by multivariate analysis. The postoperative course in these patients suggests
minimal reactivity directed against incompatible grafts on the basis of low
anti-donor blood group antibody production, in association with a favorable
rejection profile. Ten of 13 patients requiring preoperative support with an
extracorporeal membrane oxygenator survived transplantation; there were 3
additional late deaths in this subgroup (hazard ratio = 2.88, P = .05).
Conclusions: The results with pediatric cardiac transplantation continue to
improve as a result of changes in both surgical and medical protocols per-
mitting successful treatment of patients conventionally considered at high
risk or unsuitable for transplantation. (J Thorac Cardiovasc Surg
2001;121:782-91)
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donor pool and minimize pretransplantation waiting list
attrition. This study reviews our experience of heart
transplantation in an increasingly high-risk population
and the methods undertaken to care for these patients.
Patients and methods
Patients. Seventy-three patients underwent 79 heart trans-
plantations between February 1990 and December 1999 at the
Hospital for Sick Children (HSC), University of Toronto.
Patient characteristics are summarized in Table I. The follow-
up was 100% complete. The mean follow-up was 33 ± 22
months (range 3-89 months).
Surgical technique. Forty-five percent (33/73) had atrio-
atrial anastomoses and 55% (40/73) had separate bicaval
anastomoses. Mean total ischemic time was 255 ± 129 min-
utes (range 51-610 minutes). Total ischemic time exceeded 4
hours in 49% (36/73) of the patients.
P ediatric heart transplantation has gained popularityin the past decade with improved early results and
long-term outcomes.1-3 We have adopted a number of
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Blood-insulin cardioplegic solution. In the period before
April 1997, Roe’s crystalloid cardioplegic solution was used
in the first 36 (49%) patients. Our blood-insulin cardioplegic
technique, used in 37 patients since April 1997, requires no
special equipment and can accommodate the capabilities of
any donor procurement team. The donor cardioplegia dose is
calculated to be a minimum of 30 mL/kg up to a maximum of
1 L. After administration of heparin in a dose of 300 U/kg, a
volume of donor blood is withdrawn from the ascending aorta
before crossclamping and is mixed with cold cardioplegic
solution in a 1:1 ratio. Potassium, glucose, and magnesium
are added in our pharmacy to a base solution of 1000 mL of
Plasma-Lyte 148 solution (Baxter Healthcare Corporation,
Deerfield, Ill) to achieve concentrations in the crystalloid
component of the transplant cardioplegic solution as follows:
sodium 136 mmol, potassium 25 mmol, glucose 12.5 mmol,
chlorine 116 mmol, magnesium 21.5 mmol, pH 5.76 to 5.91,
and osmolality 334 to 340. Humulin (Eli Lilly and Company,
Indianapolis, Ind), biosynthetic recombinant DNA origin reg-
ular insulin, is added to achieve a final insulin concentration
of 10 U/L.
On arrival at HSC the donor organ is reperfused as follows:
recipient blood is taken from the cardiopulmonary bypass cir-
cuit and is combined in a 2:1 ratio with high-potassium (45
mmol/L) cardioplegic solution to which the following have
been added: NaHCO3 10 mEq/L, Humulin 30 U/L, and 50%
dextrose 8 mL/L (20 mmol). This solution is delivered by
pump to the donor organ in an antegrade fashion at approxi-
mately 20°C and then cooled to 15°C. The delivered concen-
tration of insulin is 10 U/L of blood cardioplegic solution.
A dose of 30 mL/kg donor weight is given before begin-
ning reimplantation and 15 mL/kg after each anastomosis.
Before crossclamp removal, the donor organ is reperfused
with a dose of low-potassium 2:1 insulin–blood cardioplegic
solution that is warmed from 25°C to 35°C during infusion.
Transplantation of ABO-incompatible organs. Since
January 1996, patients referred to the HSC in Toronto for heart
transplant assessment have been offered participation in an
experimental procedure of accepting the first available size-
compatible donor, regardless of blood group, in families who
elected cardiac transplantation after counseling regarding the
available competing surgical approaches. Eleven patients, in all
but 3 cases young infants, underwent transplantation against
standard ABO blood group antigen recommendations. Patient
characteristics for this subgroup are summarized in Table II.
Ethical committee approval was obtained for each patient.
The circulating plasma volume was sequestered at the onset
of cardiopulmonary bypass and was replaced with banked
plasma of appropriate blood type that lacked antibody direct-
ed against both donor and recipient blood groups.
Immunosuppression. Immunosuppression according to
our protocol consists of induction therapy with a rabbit-
derived polyclonal antithymocyte antibody preparation and
subsequently standard triple-drug immunosuppression with a
calcineurin inhibitor (either cyclosporine [INN: ciclosporin]
or tacrolimus), prednisone, and an antimetabolite (either 
azathioprine or mycophenolate mofetil). Intravenous methyl-
prednisolone was used for treatment of acute rejection.
Rejection surveillance was performed with endomyocardial
biopsies on a weekly basis during the first postoperative
month, every second week during the next 2 months, and
monthly up to 6 months.
Donor/recipient weight mismatch. The donor recipient
weight mismatch index for all patients was 1.6 ± 0.8 (mini-
mum: 0.7, maximum: 4.9).
Cardiac catheterization. When pulmonary vascular resis-
tance (PVR) was high or reactivity a concern, a preoperative
cardiac catheterization (n = 44) was performed. Postoperatively,
PVR was measured at the time of cardiac catheterizations per-
formed during scheduled endomyocardial biopsies. PVR was
calculated as the difference between mean pulmonary arterial
and pulmonary capillary wedge pressures divided by the car-
diac output, expressed in Wood units (millimeters of mercury
per liter per minute), and indexed for body surface area as PVRI
(millimeters of mercury per liter per square meter).
Extracorporeal membrane oxygenation (ECMO).
Thirteen patients were bridged to heart transplantation with
venoarterial ECMO—8 patients to their first heart transplanta-
tion and 5 patients to their second. In addition, 2 patients had
ECMO for post-transplantation support. Preoperative diag-
noses in this group included cardiomyopathy in 5 patients,
unsuccessful repair of congenital heart disease in 2 patients,
and graft failure in 8 patients. Two patients were cannulated in
the neck, 1 patient in both the neck and the groin, 1 patient in
the groin, and 11 patients through the chest. Average blood loss
during ECMO was 6.4 mL · kg–1 · h–1.
Definitions and statistical analysis. High-risk patients were
defined by the presence of one of the following: ECMO (n =
Table I. Clinical characteristics
No. %
No. of patients 73 100
Age 7.0 ± 6.2 y 1 d–18 y





Idiopathic cardiomyopathy 25 34
Restrictive cardiomyopathy 5 7
Congenital heart disease 32 44
Hypoplastic left heart syndrome 10 14
Cardiac tumor 1 1
Preoperative UNOS classification
Status 1 26 36
Status 2 2 3
Status 3 19 26
Status 4 23 32
Preoperative ECMO 13 18




UNOS, United Network for Organ Sharing; ECMO, extracorporeal mem-
brane oxygenation.
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13), PVRI greater than 4 Wood units (n = 12), ABO-incompat-
ible heart transplantation (n = 11), and retransplantation (n = 5).
Forty-four (32/73) percent of the patients were considered at
high risk according to this definition. Coronary artery disease
(CAD) was defined as a significant stenosis (>70%) on coro-
nary angiogram, by autopsy, or by the requirement for retrans-
plantation as a result of late graft failure. Data were analyzed by
means of SAS 6.12 for Windows (SAS Institute, Inc, Cary, NC).
Descriptive statistics include the mean ± standard deviation
(standard error in figures) for continuous variables and frequen-
cy tables for categoric variables. Late survival and time-depen-
dent morbidity were portrayed by Kaplan-Meier analysis; mul-
tivariable models were derived by means of Cox regression
using the PROC PHREG program (SAS Institute, Inc).
Results
Early outcome. The hospital mortality rate was 14%
(10/73). Causes of early and late deaths are listed in
Table III. In patients requiring pretransplantation
ECMO the hospital mortality rate was 23% (3/13).
Among the patients considered at high risk, the hospi-
tal mortality rate was 16% (5/32) (Table IV).
Survival. Survival at 1 and 5 years was 85% ± 4% and
73% ± 8%, respectively (Fig 1). Five patients died during
the follow-up period. Three patients died of post-trans-
plantation lymphoproliferative disease (PTLD) and 2
patients of coronary artery disease (CAD) (Table III).
Freedom from death or retransplantation at 1 and 5 years
was 80% ± 5% and 68% ± 9%, respectively (Fig 2).
Freedom from any of the following events—death,
retransplantation, CAD, or PTLD—was 79% ± 5% and
45% ± 11% at 1 and 5 years, respectively (Fig 3).
Multivariate analysis showed that ECMO (hazard ratio
2.88, P = .05) was an independent risk factor for death.
Multivariate analysis also suggests that crystalloid car-
dioplegia (hazard ratio for blood-insulin cardioplegia
0.25, P = .08) was significant as a risk factor for death.
Table II.  Patient characteristics for ABO-incompatible heart transplants
Diagnosis Age at HTx Recipient blood group Donor blood group Duration of follow-up Comments
DCM 7.5 y O A 209 d Died, PTLD
HLHS 25 d O AB 4 y Alive
DCM 149 d O B 3 d Re-Tx, alive 3.2 y
HLHS 1 d O A 30 d Died, graft hypertrophy
DCM 1.2 y O B 24 d Died, respiratory failure
HLHS 63 d A B 2.3 y Alive
RAI 55 d O A 1.9 y Alive
HLHS 2 d O B 1.2 y Alive
HLHS 50 d O B 345 d Alive
HLHS 1.2 y O A 274 d Alive
HLHS 83 d O A 92 d Alive
DCM, Dilated cardiomyopathy; HLHS, hypoplastic left heart syndrome; RAI, right atrial isomerism; HTx, heart transplantation; Re-Tx, retransplantation.
Table III.  Early and late mortality
No. %
Early mortality 10 14




Pulmonary venous obstruction 1
Multiple organ failure 2
Graft hypertrophy 1
Late mortality 5 7
Cause of death in summary
PTLD 3
CAD 2
Total No. (early and late) of deaths 15/73 21
PTLD, Post-transplantation lymphoproliferative disease; CAD, coronary
artery disease.





Low-risk patients 41 5 12
High-risk patients 32 5 16
ECMO 32 5 16
ABO-I 11 2 18
High PVRI 12 2 17
Re-Tx 6 1 17
Total No. of hospital deaths 10/73 14
ECMO, Extracorporeal membrane oxygenation; ABO-I, ABO-incompatible
transplantation; PVRI, pulmonary vascular resistance index; Re-Tx, retrans-
plantation.
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Preoperative PVR, ABO incompatibility, and total
ischemic time were not predictors of death. Actuarial
survival was significantly decreased for patients with
pretransplantation ECMO compared with those without
(P < .01) (Fig 4). Actuarial survival was significantly
lower for patients receiving crystalloid cardioplegia ver-
sus blood cardioplegia (P < .01) (Fig 5).
PVR. PVR was 4.8 ± 6.6 (mean ± SD Wood units)
preoperatively, 4.8 ± 6.7 at 1 month, and 2.4 ± 2.5 at
1 year after transplantation, respectively (before
transplantation vs 1 year; P = .03; factorial analysis
of variance). At the corresponding time intervals,
PVRI was 3.4 ± 2.8 (mean ± SD Wood units × m2),
2.6 ± 2.4 and 1.9 ± 1.5, respectively (before trans-
Fig 1. Actuarial survival for all patients undergoing heart transplantation.
Fig 2. Actuarial freedom from death or retransplantation (re-Tx).
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plantation vs 1 year; P = .007 [factorial analysis of
variance]). Preoperatively, PVRI was higher than 4
Wood units × m2 in 12 patients (16%), higher than 6
Wood units × m2 in 8 patients (11%), and higher than
8 Wood units × m2 in 2 patients (3%). Preoperative
PVR or PVRI was not a risk factor for death by mul-
tivariate analysis.
Superior vena cava (SVC) stenosis. Three patients
had significant SVC obstruction postoperatively and
required stent implantation in the SVC.
Immunosuppression. Immunosuppressive therapy
at discharge and at follow-up is shown in Fig 6.
Waiting list issues. Mean time on the waiting list for
all patients who eventually received a heart transplant
Fig 3. Actuarial freedom from death, retransplantation (re-Tx), coronary artery disease (CAD), or post-transplan-
tation lymphoproliferative disease (PTLD).
Fig 4. Actuarial survival for patients with pretransplantation extracorporeal membrane oxygenation (ECMO) 
versus those without. ReTx, Retransplantation.
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was 78 ± 98 days (median 45 days; range 0-540 days).
Nineteen percent (22/116) of patients listed for a heart
transplant died after a mean of 30 ± 42 days (range 1-
184 days) on the waiting list. Nine patients were listed
for heart transplantation but improved clinically and
were subsequently removed from the list. Surgical
alternatives were pursued in 7 patients originally listed
for heart transplantation. Five patients were still listed
for transplantation as of December 31, 1999.
Since January 1996, 22 infants less than 6 months of
age were listed for transplantation. Two patients died at
6 and 9 weeks after being listed. Fifteen patients under-
went cardiac transplantation; 9 received ABO-incom-
patible grafts and 6 patients underwent ABO-compati-
ble transplantation. Two patients were removed from
the list due to cerebral bleeding (n = 1) and the pres-
ence of a lethal genetic syndrome (n = 1). Three
patients underwent other surgical options. Thus, on an
Fig 5. Actuarial survival for patients receiving blood cardioplegia versus crystalloid cardioplegia. ReTx, Retrans-
plantation.
Fig 6. Immunosuppression at discharge from hospital and at late follow-up. CyA, Cyclosporine; Tacrol, tacrolimus;
Pred, prednisone; Aza, azathioprine; MMF, mycophenolate mofetil.
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intent-to-treat basis, 89% (16/18) survived the waiting
list period. Before 1996, 12 patients less than 6 months
of age were listed for heart transplantation. Seven died,
2 underwent transplantation, and 3 patients underwent
the modified Norwood procedure. Thus, before 1996,
only 17% (2/12) listed for heart transplantation actual-
ly underwent this procedure.
CAD. CAD developed in 7 (7/63, 11%) patients after
transplantation. Two patients died of CAD, 1 of whom
underwent a second transplant operation. Three
patients had stenosis of the left anterior descending
artery on follow-up coronary angiography: one of these
patients underwent successful stent insertion in the left
anterior descending coronary artery; one patient has
been listed for retransplantation because of progressive
heart failure and CAD.
PTLD. PTLD developed in 9 (9/63, 14%) patients
after transplantation. Three of these patients have died
as a result of PTLD. Two additional patients with
PTLD died as a result of coexisting CAD. The remain-
ing 4 patients in whom PTLD developed are in remis-
sion at most recent follow-up.
Discussion
Over the past decade, pediatric heart transplantation
has become successful therapy for end-stage congeni-
tal heart disease and idiopathic cardiomyopathy.1-3 The
survival at 1 and 5 years in our experience is similar to
what has been previously reported by the Pediatric
Heart Transplant Study Group,4 by the Registry of the
International Society of Heart and Lung Trans-
plantation,1 and by others.2 Kanter and associates2 pub-
lished excellent results with a 4% early (30 days) mor-
tality rate but with 5-year survivals similar to those
reported in our series. Our experience indicates that
favorable survival results can be achieved even in
recipients with clinical features traditionally consid-
ered to put them at high risk for transplantation.
Wider application of pediatric heart transplantation is
prevented by the shortage of donor organs of appropriate
size, especially in the neonatal recipients. Waiting list
mortality for infants can be as high as 40%, especially in
those centers accepting a large proportion of patients with
ductus-dependent cardiac lesions.5,6 The traditionally
accepted premise of donor-recipient blood group com-
patibility prevents the more efficient allocation of organs
on the basis of medical urgency. We have also observed
that organs from blood group AB or B pediatric donors
may not be used due to scarcity of appropriately sized
ABO-compatible recipients, despite recipient registration
with national and international networks.
Our waiting list outcomes are comparable with those
of previously reported studies.7 Waiting list attrition in
the neonatal group has declined in our recent experi-
ence. We attribute this decline to improvement in the
medical management of the ductus-dependent circula-
tion. However, we suggest that the use of ABO-incom-
patible grafts further contributed to a decline in waiting
list attrition and improved organ allocation in this sub-
set of patients.
ABO-incompatible cardiac transplantation was per-
formed in infants to increase the availability of organs
in this high-risk group. In a survey from 66 centers
worldwide, Cooper8 found that 8 (0.16%) of 4895
patients underwent inadvertent ABO-incompatible
heart transplantation. The risk of hyperacute rejection
was very high (5/8) in this group, with only 2 long-term
survivors.
Our experience indicates that ABO-incompatible
transplantation can be performed without significantly
increased mortality or morbidity. We attribute the lack
of hyperacute rejection in our experience to the pre-
emptive removal of anti-A and anti-B antibodies during
plasma exchange on bypass before graft reperfusion
and/or the low pretransplantation antibody titers typical
of recipients in the first year of life. This result is pre-
dicted by both experimental evidence9 and limited
experience in renal transplantation,10 in which the risk
of hyperacute rejection is related to pre-existing anti-
body titers in the recipient. Patients receiving ABO-
incompatible grafts showed a tendency to produce
lower levels of antibodies directed against the incom-
patible blood group antigen than against the nonex-
pressed antigen. Furthermore, little or no evidence of
vascular rejection was seen, and persistent cellular
rejection did not occur during follow-up in recipients
of ABO-incompatible grafts. No patient in this sub-
group of patients has had CAD develop during the lim-
ited follow-up extending to 4 years. Thus, the clinical
and immunologic course would imply that a degree of
operational tolerance had occurred in this subset of
patients, although longer follow-up is clearly required
to make this determination.
We found that pretransplantation use of ECMO was a
risk factor affecting post-transplantation survival.
Nevertheless, the 5-year survival results may be consid-
ered acceptable in the ECMO group considering the pre-
transplantation status of these patients. We found that
ECMO was a useful rescue intervention in rapidly dete-
riorating cardiomyopathy and as a bridge to retransplan-
tation in early or late graft dysfunction. The results from
other studies support these recommendations.11
Multivariable analysis was consistent with protective
effects of blood-insulin cardioplegia. Our data also
indicate that prolonged ischemic time (up to 10 hours)
can be safely used with blood-insulin cardioplegia.
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Since blood-insulin cardioplegia has been used more
recently, it could be argued that the improved results
are also in part attributable to greater experience after
an initial learning curve. The beneficial effects of
blood-insulin cardioplegia, however, are supported by
experimental12 and clinical13 studies.
The precise mechanisms that mediate the protective
effects of insulin have not been delineated but may be
attributable to the stimulation of specific signaling cas-
cades by this hormone. Insulin binding stimulates tyro-
sine autophosphorylation of the insulin receptor and acti-
vates its intrinsic tyrosine kinase activity, leading to the
phosphorylation of insulin receptor substrates and the
subsequent activation of phosphatidylinositol-3-OH
kinase.14 The anti-apoptotic effects of insulin and
insulin-like growth factor-1 have been linked to the acti-
vation of signaling molecules such as insulin receptor
substrate-1,15,16 phosphatidylinositol-3-OH kinase,17,18
and protein kinase B/Akt.19 Protein kinase B provides a
survival signal that protects cells from apoptosis
induced by diverse stresses, including withdrawal of
the survival factor insulin-like growth factor-1 from
neuronal cells19 and by detachment of cells from the
extracellular matrix.20 In the current study, however,
the effect of insulin cannot be isolated from the effect
of blood cardioplegia because both factors operated
concomitantly. It should also be noted that in the pre-
sent study, improved results with blood-insulin cardio-
plegia were documented in comparison with a specific
composition of crystalloid cardioplegic solution that
may be inferior to alternative crystalloid solutions used
successfully by other groups.2
The incidence of SVC stenosis necessitating stent
implantation after cavo-caval anastomosis techniques
has been relatively high in our experience, despite the
use of interrupted suture technique designed to prevent
anastomotic narrowing. Six additional patients not
included in the current study recently underwent trans-
plantation by means of a cavo-caval technique, and 3 of
them have required stent implantation. The hemody-
namic significance of SVC stenosis necessitating stent
implantation and that of less severe stenoses evident
angiographically are unknown and deserve serious con-
sideration in the choice of venous reconnection tech-
niques, particularly in the infant age group.
Our results indicate that pediatric cardiac transplant
recipients are subject to a continuing substantial risk of
potentially lethal complications including PTLD and
CAD. The incidence of PTLD is comparable with that
observed in previous studies2,7,21 and is higher than typ-
ically observed in adult recipients.22 Conversely, the
incidence of CAD in our study appears to be similar to
that noted in other pediatric reviews2,23 and lower than
typically seen in adult recipients.24 These complica-
tions, as well as the continuing risk of graft rejection,
reflect the inadequacies of current immunosuppressive
therapy.
Preoperative PVR higher than 5 Wood units and a
transpulmonary gradient exceeding 15 mm Hg have
been considered as contraindications to heart trans-
plantation in adults.25 Addonizio and associates26
showed that PVRI was more discriminating than PVR
in predicting postoperative right ventricular failure and
that patients with PVRI in the range of 6 to 10 Wood
units × m2 were considered at high risk for right ven-
tricular failure. However, our study did not reveal that
higher PVR or PVRI was a risk factor for early or late
death, a finding consistent with the Pittsburgh data.25
Our experience indicates that there is no upper limit to
baseline pretransplantation PVR that precludes suc-
cessful cardiac transplantation, provided that evidence
of reactivity of the pulmonary vascular bed is revealed
at the pretransplantation cardiac catheterization. These
considerations also apply to patients with restrictive
cardiomyopathy who frequently have increased PVR
early in the course of their disease.
Conclusions
This experience indicates that strategies designed to
increase organ availability in pediatric cardiac trans-
plantation, including the use of ABO-incompatible
grafts and substantial extension of acceptable donor
ischemic times, can be pursued without significantly
increased morbidity or mortality. Further, the use of a
blood-insulin cardioplegia protocol appears to confer
improved graft protection despite relatively long donor
ischemic times.
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Discussion
Dr Thomas L. Spray (Philadelphia, Pa). The authors have
shown that results with cardiac transplantation in pediatric
patients have continued to improve, and they raise the stimu-
lating possibility of increasing use of ABO-incompatible
donors for infant recipients. The principle of ABO-incompat-
ible transplantation has been validated in the renal transplant
experience, and Dr Coles and his group have been pioneers in
applying this procedure to pediatric patients. The benefits of
ABO-incompatible transplantation presumably will be the
ability to use potentially wasted organs and possibly decrease
waiting times for patients in common blood groups, such as
group O. The authors, unfortunately, however, did not assess
whether organs are being wasted for lack of suitable recipi-
ents in the Canadian organ procurement system. Such a situ-
ation in the United States is uncommon because of the rela-
tively large number of infants listed at any given time,
reflecting the preference for transplantation for hypoplastic
left heart syndrome in a few US centers. I believe, though, on
the basis of Dr Coles’ study, that the organ distribution sys-
tem in the United States would be well served by analyzing
the potential effects of ABO-incompatible transplantation on
waiting times for pediatric patients. ABO-incompatible trans-
plantation possibly could provide a great opportunity to
decrease waiting times in the sickest patients if it does not
divert organs from patients in less common blood groups. 
Although the authors have presented a large series of pedi-
atric transplants with good results, the study is actually not
designed to show that there are improving results in high-risk
patients. The authors defined high-risk patients arbitrarily as
those receiving ECMO support, those with ABO-incompati-
Dr Coles. Thank you for your comment, Dr Spray, and
your pertinent questions. 
With regard to your comment, in several of the patients
who underwent ABO-incompatible transplantation, we were
offered hearts that otherwise would have been wasted, both
from Canada and from the United States. Thus, I think there
are unique recipients with respect to blood group who would
benefit from incompatible transplantation and therefore
improve the global use of neonatal organs. 
To answer your question about age threshold, we use ABO-
incompatible donor organs primarily in infants. Two older
patients, however, 1 of whom was receiving ECMO support,
had high pretransplantation anti-blood group–directed anti-
bodies. These antibodies were removed by means of plasma
exchange on bypass and the patients have done well postop-
eratively. One interesting finding is that they actually had
lower titers against the relevant donor blood group than
against irrelevant blood groups, suggesting a kind of opera-
tional tolerance, at least with respect to the donor blood
group. Therefore, I think this technique could be cautiously
applied to older patients and possibly even adults. 
We think that SVC stenosis is an underestimated complica-
tion. I believe a careful review of postoperative angiograms
obtained at the time of biopsy will often show some narrowing,
regardless of the techniques that are used, such as interrupted
suture techniques and patching to prevent this complication. As
you mentioned, several of our patients required stent implanta-
tion. On the basis of that experience, we now prefer to use con-
ventional atrial anastomosis in patients less than 10 kg. 
Your point is well taken. It is not possible to separate the
era effect from the blood effect from the insulin effect.
However, the differences were so dramatic that we would be
disinclined to revisit the crystalloid era. 
Dr Carl L. Backer (Chicago, Ill). I want to echo Dr
Spray’s concerns about blood-insulin cardioplegia being the
reason for your improved results. Our series is parallel to
yours, approximately 80 transplants in 10 years. For the first
40 patients we had a 12% mortality; for the last 40 transplants
we have had no mortality. The last time period has seen many
changes, with the use of modified ultrafiltration, bicaval tech-
nique, aprotinin, and changes in immunosuppression proto-
cols. It is very difficult to sort out the changed cardioplegia
technique as a single item that has improved your results. 
Dr Coles. I agree with your comments.
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ble transplants, those with an elevated PVRI, and those
undergoing retransplantation; however, they showed in their
results that only ECMO is in fact a risk factor for mortality.
The arbitrarily defined high-risk group was not the basis for
the study, and results over time in this subset of patients were
not examined specifically. 
I have several questions for the authors, primarily to gain
more information on their experience. 
The addition of blood-insulin cardioplegia seems to be
associated with improved survival, although only 3 of the 10
early deaths in the experience were related to graft failure.
Could you comment on the function of the hearts after the use
of this different cardioplegia technique, and could you elabo-
rate on why you believe this has fundamentally changed the
morbidity and mortality of the procedure? 
Is the improvement in results just a time-related phenome-
non or is it in fact related to the cardioplegia technique? Was
the date of transplantation ever placed in the model for uni-
variate analysis? 
When you do ABO-incompatible transplantations, do
you modify the use of the blood-insulin cardioplegia so that
the donor heart is reperfused not with recipient blood car-
dioplegic solution during the implantation but with a mod-
ified solution? If not, do you think that the possible admin-
istration of recipient blood antigen to the donor has any
deleterious consequences when you give cardioplegia? Do
you try to wash the blood cardioplegic solution from the
donor out of the heart before it is actually exposed to recip-
ient blood? 
I noticed that ABO-incompatible transplantation in your
experience was used primarily in infants. The experience in
adult transplantation crossing blood groups has not been very
favorable, with both early and late graft dysfunction in cases
in which accidental ABO-incompatible transplantation has
been performed. Do you believe this technique can be used
for older children and adults? If not, at what age would you
consider a patient no longer suitable for ABO-incompatible
transplantation? 
One final question is related to the high incidence of SVC
stenosis noted in the bicaval technique group of transplants.
On the basis of the relative frequency of obstruction of the
SVC, do you now continue to advocate bicaval anastomosis
or have you considered reverting to the atrial anastomosis,
especially in young children, to prevent this complication? 
